Jazz Pharmaceuticals plc
Jazz Pharmaceuticals Receives FDA Approval for Ziihera to Treat HER2-Positive Biliary Tract Cancer
Summary
On November 20, 2024, Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Ziihera (zanidatamab-hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC). The approval is based on a 52% objective response rate and a median duration of response of 14.9 months from the HERIZON-BTC-01 trial. Continued approval may depend on the results of a confirmatory trial. The company plans to host an investor webcast on December 11, 2024, to discuss the clinical data, patient need, and commercialization strategy for Ziihera.
Profitelligence Alerts
Get alerts for JAZZ
Be first to know when Jazz Pharmaceuticals plc files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company that focuses on developing life-changing medicines for patients in various therapeutic areas. The company's primary function is to research, manufacture, and market drugs that address unmet medical needs, particularly in the fields of neuroscience, oncology, and sleep medicine. Jazz Pharmaceuticals has gained prominence for its innovative products such as Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia. Headquartered in Dublin, Ireland, the company operates extensively across North America and Europe, working to advance scientific research in pharmaceuticals. By prioritizing patient care and survival, Jazz Pharmaceuticals plays a significant role in the pharmaceutical industry with its commitment to developing novel therapies. Moreover, the company's strategic collaborations and acquisitions enable it to expand its product portfolio and impact the healthcare sector positively. Jazz Pharmaceuticals continues to be a key player in transforming patient care for complex conditions.
Official SEC Documents
Advertisement